Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer
The purpose of this study is to study the efficacy of hyperthermic intraperitoneal chemotherapy in the treatment of patients with locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy. It is a multicentric and randomised phase III trial.
Advanced Gastric Adenocarcinoma
PROCEDURE: D2 lymphadenectomy|PROCEDURE: Systemic chemotherapy|PROCEDURE: HIPEC
Overall survival, From the date of surgery to the date of death or to the end of follow-up, 5 years
Recurrence-free survival, From the date of surgery to the date of recurrence or to the end of follow-up, 5 years|Locoregional-free survival, From the date of surgery to the date of locoregional recurrence or to the end of follow-up, 5 years|Hepatic metastases-free survival, From the date of surgery to the date of recurrence or to the end of follow-up, 5 years
The purpose of this study is to study the efficacy of hyperthermic intraperitoneal chemotherapy in the treatment of patients with locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy. It is a multicentric and randomised phase III trial.